Kivizidiale (Timolol, Travoprost)

Timolol reduces the production of aqueous humor by blocking β‑adrenergic receptors in the ciliary body, while travoprost increases uveoscleral outflow by activating prostaglandin F2α receptors. The complementary mechanisms result in a greater overall reduction of intra‑ocular pressure than either agent alone.

The dosing regimen for Kivizidiale is determined by the prescribing clinician. Typically, one drop is instilled in the affected eye(s) once daily, but the exact frequency and duration depend on the individual patient's response and clinical judgment.

Safety data for timolol and travoprost in pregnancy and lactation are limited. The product should be used only if the potential therapeutic benefit justifies any possible risk to the fetus or nursing infant, and this decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with single‑agent drops, Kivizidiale offers a dual mechanism—decreasing aqueous humor production and increasing outflow—providing stronger intra‑ocular pressure control. This can reduce the need for multiple separate medications, potentially improving adherence while maintaining a safety profile similar to its individual components.

Store Kivizidiale at room temperature, below 25 °C, in the original packaging. Protect the bottle from direct sunlight, moisture and extreme temperatures. Keep the dropper tip clean and avoid contaminating the solution.

Kivizidiale is applied as an ocular solution. The patient should wash their hands, tilt the head back, pull down the lower eyelid, and place one drop into the conjunctival sac of each prescribed eye. Close the eye gently for a few seconds and avoid blinking excessively.

Serious risks include severe allergic reactions (e.g., rash, swelling, breathing difficulty), a sudden increase in intra‑ocular pressure, systemic cardiovascular effects such as bradycardia, hypotension or chest pain, and respiratory distress in patients with asthma. Immediate medical attention is required if any of these occur.

Kivizidiale is contraindicated in patients with known hypersensitivity to timolol, travoprost, or any excipients, as well as in individuals with severe asthma, chronic obstructive pulmonary disease, sinus bradycardia, or advanced heart block. It should also be avoided in patients with active ocular infections or inflammation.